^
Association details:
Biomarker:HER-2 G776insV_G
Cancer:Non Small Cell Lung Cancer
Drug:erlotinib (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272

Excerpt:
In contrast, NCI-H1781 cells, known to carry wild-type EGFR and the G776insV_G/C mutation of ERBB2 ( 9), were resistant to erlotinib. However, these cells were highly sensitive to HKI-272 with an IC50 of 0.085 μmol/L.
DOI:
10.1158/0008-5472.CAN-06-0971